These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17995469)

  • 1. Analysis and interpretation of results based on patient-reported outcomes.
    Sloan JA; Dueck AC; Erickson PA; Guess H; Revicki DA; Santanello NC;
    Value Health; 2007; 10 Suppl 2():S106-15. PubMed ID: 17995469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting and reporting results based on patient-reported outcomes.
    Revicki DA; Erickson PA; Sloan JA; Dueck A; Guess H; Santanello NC;
    Value Health; 2007; 10 Suppl 2():S116-24. PubMed ID: 17995470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denouement: a patient-reported observation.
    Chauhan C
    Value Health; 2007; 10 Suppl 2():S146-7. PubMed ID: 17995473
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient-reported outcomes to support medical product labeling claims: FDA perspective.
    Patrick DL; Burke LB; Powers JH; Scott JA; Rock EP; Dawisha S; O'Neill R; Kennedy DL
    Value Health; 2007; 10 Suppl 2():S125-37. PubMed ID: 17995471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes.
    Sloan JA; Halyard MY; Frost MH; Dueck AC; Teschendorf B; Rothman ML;
    Value Health; 2007; 10 Suppl 2():S59-63. PubMed ID: 17995474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is sufficient evidence for the reliability and validity of patient-reported outcome measures?
    Frost MH; Reeve BB; Liepa AM; Stauffer JW; Hays RD;
    Value Health; 2007; 10 Suppl 2():S94-S105. PubMed ID: 17995479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ; Burke LB; Erickson P
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcome instrument selection: designing a measurement strategy.
    Snyder CF; Watson ME; Jackson JD; Cella D; Halyard MY;
    Value Health; 2007; 10 Suppl 2():S76-85. PubMed ID: 17995477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Missing data in confirmatory clinical trials.
    Flyer P; Hirman J
    J Biopharm Stat; 2009 Nov; 19(6):969-79. PubMed ID: 20183459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.
    Sloan JA; Berk L; Roscoe J; Fisch MJ; Shaw EG; Wyatt G; Morrow GR; Dueck AC;
    J Clin Oncol; 2007 Nov; 25(32):5070-7. PubMed ID: 17991923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes: conceptual issues.
    Rothman ML; Beltran P; Cappelleri JC; Lipscomb J; Teschendorf B;
    Value Health; 2007; 10 Suppl 2():S66-75. PubMed ID: 17995476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
    DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
    Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mixture gatekeeping procedure based on the Hommel test for clinical trial applications.
    Brechenmacher T; Xu J; Dmitrienko A; Tamhane AC
    J Biopharm Stat; 2011 Jul; 21(4):748-67. PubMed ID: 21516567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
    Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
    Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.
    Coons SJ; Kothari S; Monz BU; Burke LB
    Clin Pharmacol Ther; 2011 Nov; 90(5):743-8. PubMed ID: 21993428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.
    Wiklund I
    Fundam Clin Pharmacol; 2004 Jun; 18(3):351-63. PubMed ID: 15147288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
    Brozek JL; Guyatt GH; Schünemann HJ
    Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primer: measuring the effects of treatment in clinical trials.
    Ward MM
    Nat Clin Pract Rheumatol; 2007 May; 3(5):291-7. PubMed ID: 17471248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What we want versus what we can get: a closer look at failure time endpoints for cardiovascular studies.
    Song R; Cook TD; Kosorok MR
    J Biopharm Stat; 2008; 18(2):370-81. PubMed ID: 18327727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting on the FDA draft guidance on patient-reported outcomes.
    Dueck AC; Sloan JA
    Value Health; 2007; 10 Suppl 2():S64-5. PubMed ID: 17995475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.